BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai). J Dig Dis 2021;22:176-86. [PMID: 33470535 DOI: 10.1111/1751-2980.12970] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Tong Y, Zhang M, Zhang F, Xiao J, Wang Y, Zhang W, Huang S, Peng C, Zhuge Y, Zhang B. Clinical outcome comparison between transjugular intrahepatic portosystemic shunt and endoscopic treatment in patients with cavernous transformation of the portal vein presenting with variceal bleeding: A retrospective study.. [DOI: 10.21203/rs.3.rs-2396121/v1] [Reference Citation Analysis]
2 Ding J, Zhao F, Miao Y, Liu Y, Zhang H, Zhao W. Nomogram for Predicting Portal Vein Thrombosis in Cirrhotic Patients: A Retrospective Cohort Study. J Pers Med 2023;13. [PMID: 36675764 DOI: 10.3390/jpm13010103] [Reference Citation Analysis]
3 Tie J, Gou X, He C, Li K, Yuan X, Jia W, Niu J, Han N, Xu J, Zhu Y, Wang W. Transjugular intrahepatic collateral-systemic shunt is effective for cavernous transformation of portal vein with variceal bleeding.. [DOI: 10.21203/rs.3.rs-2282724/v1] [Reference Citation Analysis]
4 Wang L, Guo X, Bai Z, Yin Y, Xu S, Pan J, Mancuso A, Noronha Ferreira C, Qi X. Impact of Asymptomatic Superior Mesenteric Vein Thrombosis on the Outcomes of Patients with Liver Cirrhosis. Thromb Haemost 2022. [PMID: 36179738 DOI: 10.1055/s-0042-1756648] [Reference Citation Analysis]
5 Tarar ZI, Farooq U, Kamal F, Nawaz A, Saleem S, Ghous G, Basar O, Chela HK, Tahan V, Daglilar E. Safety of anticoagulation use for treatment of portal vein thrombosis in liver cirrhosis and its effect on hospital-based outcomes: an insight from a US nationwide database. Postgrad Med J 2022:postgradmedj-2022-141915. [PMID: 36008113 DOI: 10.1136/pmj-2022-141915] [Reference Citation Analysis]
6 He Y, Yao H, Ageno W, Méndez-Sánchez N, Guo X, Qi X. Review article: thromboelastography in liver diseases. Aliment Pharmacol Ther 2022;56:580-91. [PMID: 35698893 DOI: 10.1111/apt.17080] [Reference Citation Analysis]
7 Pan J, Wang L, Gao F, An Y, Yin Y, Guo X, Nery FG, Yoshida EM, Qi X. Epidemiology of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis. European Journal of Internal Medicine 2022. [DOI: 10.1016/j.ejim.2022.05.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wang L, Guo X, Shao X, Xu X, Zheng K, Wang R, Chawla S, Basaranoglu M, Qi X. Association of endoscopic variceal treatment with portal venous system thrombosis in liver cirrhosis: a case–control study. Therap Adv Gastroenterol 2022;15:175628482210875. [DOI: 10.1177/17562848221087536] [Reference Citation Analysis]
9 Xing Y, Jiang Y, Xing S, Mao T, Guan G, Niu Q, Zhao X, Zhou J, Jing X. Neutrophil extracellular traps are associated with enhanced procoagulant activity in liver cirrhosis patients with portal vein thrombosis. J Clin Lab Anal 2022;:e24433. [PMID: 35435260 DOI: 10.1002/jcla.24433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Xing Y, Tian Z, Jiang Y, Guan G, Niu Q, Sun X, Han R, Jing X. A practical nomogram based on systemic inflammatory markers for predicting portal vein thrombosis in patients with liver cirrhosis. Annals of Medicine 2022;54:302-9. [DOI: 10.1080/07853890.2022.2028893] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Shukla A, Giri S. Portal Vein Thrombosis in Cirrhosis. J Clin Exp Hepatol 2022;12:965-79. [PMID: 35677518 DOI: 10.1016/j.jceh.2021.11.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Koh JH, Liew ZH, Ng GK, Liu HT, Tam YC, De Gottardi A, Wong YJ. Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: A systematic review and meta-analysis. Dig Liver Dis 2022;54:56-62. [PMID: 34393072 DOI: 10.1016/j.dld.2021.07.039] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
13 Xu S, Guo X, Yang B, Romeiro FG, Primignani M, Méndez-Sánchez N, Yoshida EM, Mancuso A, Tacke F, Noronha Ferreira C, De Stefano V, Qi X. Evolution of Nonmalignant Portal Vein Thrombosis in Liver Cirrhosis: A Pictorial Review. Clin Transl Gastroenterol 2021;12:e00409. [PMID: 34597281 DOI: 10.14309/ctg.0000000000000409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Yeoh SW, Kok HK. Transjugular intrahepatic portosystemic shunts in portal vein thrombosis: A review. J Dig Dis 2021;22:506-19. [PMID: 34323378 DOI: 10.1111/1751-2980.13035] [Reference Citation Analysis]
15 Ding JN, Zhao WF. Mechanism, diagnosis, and treatment of portal vein thrombosis in cirrhosis. Shijie Huaren Xiaohua Zazhi 2021; 29(12): 670-676 [DOI: 10.11569/wcjd.v29.i12.670] [Reference Citation Analysis]
16 Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai). J Dig Dis 2021;22:176-86. [PMID: 33470535 DOI: 10.1111/1751-2980.12970] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]